Because IgM is highly effective at inducing complement, and the N-glycans on IgM were significantly altered in severe vs nonsevere COVID-19 patients, we sought to determine if we could confirm the previously reported increases of SARS-CoV-2 antigen-specific complement deposition. This evidence concerns the gene CD40LG and COVID-19.